O
Orthofix Medical Inc.
OFIXCIK 0000884624NasdaqAcceleratedSurgical & Medical Instruments & ApparatusFY ends Dec 23
Period
FY 2025
Revenue
$822.31M
Net Income
$-92.19M
Total Assets
$850.65M
Equity
$450.04M
Shares Out
40.14M
Op. Cash Flow
$33.35M
Business
Orthofix Medical Inc. is a global medical technology company that develops and markets devices and therapies for musculoskeletal and spinal conditions. Its offerings include spinal hardware, bone growth stimulators (PEMF and LIPUS), biologics, the 7D FLASH navigation system, and orthopedic fixation and limb‑lengthening solutions with related services. The business is organized into two reporting segments—Global Spine and Global Orthopedics—covering bone growth therapies, spinal implants, enabling technologies, biologics, and internal and external fixation. It sells products globally through direct sales, distributors, and consignment or loan models to hospitals and ambulatory surgery centers.
Summary from filing dated 2025-02-25
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net sales | 822 | 799 | 747 | 461 | 464 | |
| Cost of sales | 256 | 254 | 260 | 124 | 115 | |
| Gross profit | 566 | 546 | 486 | 337 | 350 | |
| Sales, general, and administrative | 554 | 533 | 530 | 309 | — | |
| Research and development | 66 | 74 | 80 | 49 | 50 | |
| Acquisition-related amortization, impairment, and remeasurement (Note 17) | 27 | 24 | 15 | — | — | |
| Operating loss | −81 | −85 | −139 | −13 | −8 | |
| Interest expense, net | −17 | −30 | −9 | −1 | −2 | |
| Other (expense) income, net | 8 | −10 | −938,000 | −3 | −3 | |
| Loss before income taxes | −91 | −124 | −149 | −18 | −13 | |
| Income tax expense | −1 | −2 | −3 | −2 | −25 | |
| Net loss | −92 | −126 | −151 | −20 | −38 | |
| Basic (per share) | −2.33 | −3.3 | −4.12 | −0.98 | −1.95 | |
| Diluted (per share) | −2.33 | −3.3 | −4.12 | −0.98 | −1.95 | |
| Basic (shares) | 40 | 38 | 37 | 20 | 20 | |
| Diluted (shares) | 40 | 38 | 37 | 20 | 20 | |
| Unrealized loss on debt securities | — | — | −1 | 395,000 | −942,000 | |
| Currency translation adjustment | 5 | −3 | 1 | −2 | −3 | |
| Other comprehensive income (loss), before tax | 5 | −3 | 83,000 | −1 | −3 | |
| Other comprehensive income (loss), net of tax | 5 | −3 | 83,000 | −1 | −3 | |
| Comprehensive loss | −87 | −129 | −151 | −21 | −42 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 82 | 83 | 33 | 51 | 88 | |
| Restricted cash | 3 | 3 | 5 | — | — | |
| Accounts receivable, net of allowances of $8,308 and $7,418, respectively | 136 | 135 | 128 | 83 | 79 | |
| Inventories | 172 | 189 | 222 | 100 | 83 | |
| Prepaid expenses and other current assets | 24 | 23 | 32 | 22 | 20 | |
| Total current assets | 417 | 433 | 420 | 256 | 270 | |
| Property, plant, and equipment, net | 129 | 140 | 159 | 58 | 59 | |
| Intangible assets, net | 73 | 99 | 117 | 47 | 53 | |
| Goodwill | 195 | 195 | 195 | 71 | 71 | |
| Other long-term assets | 37 | 26 | 33 | 26 | 24 | |
| Total assets | 851 | 893 | 925 | 459 | 477 | |
| Accounts payable | 58 | 49 | 58 | 28 | 26 | |
| Current portion of long-term debt | 0 | 0 | 1 | — | — | |
| Current portion of finance lease liability | 837,000 | 755,000 | 708,000 | 652,000 | 3 | |
| Other current liabilities | 111 | 119 | 105 | 55 | 77 | |
| Total current liabilities | 170 | 169 | 165 | 84 | 106 | |
| Long-term debt | 157 | 157 | 93 | — | — | |
| Long-term portion of finance lease liability | 17 | 18 | 19 | 19 | 20 | |
| Other long-term liabilities | 56 | 47 | 50 | 19 | 14 | |
| Total liabilities | 401 | 390 | 327 | 122 | 140 | |
| Contingencies (Note 13) | — | — | — | — | — | |
| Common shares $0.10 par value; 100,000 shares authorized; 39,834 and 38,486 issued and outstanding as of December 31,2025 and 2024, respectively | 4 | 4 | 4 | 2 | 2 | |
| Additional paid-in capital | 814 | 780 | 746 | 335 | 314 | |
| Accumulated deficit | −368 | −276 | −150 | 1 | 21 | |
| Accumulated other comprehensive income (loss) | 618,000 | −4 | −1 | −1 | — | |
| Total shareholders equity | 450 | 503 | 599 | 337 | 337 | |
| Total liabilities and shareholders equity | 851 | 893 | 925 | 459 | 477 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation, amortization, and impairment | 77 | 60 | 53 | — | — | |
| Inventory reserve expenses | 31 | 26 | 28 | 15 | 11 | |
| Amortization of inventory fair value step-up | — | 12 | 36 | — | — | |
| Amortization of operating lease assets, debt costs, and other assets | 6 | 16 | 7 | 3 | 3 | |
| Provision for expected credit losses | 2 | 2 | 820,000 | 2 | — | |
| Deferred income taxes | 223,000 | 2 | 579,000 | 314,000 | 24 | |
| Share-based compensation expense | 29 | 32 | 36 | 18 | 15 | |
| Loss on disposal of fixed assets | 1 | 2 | 2 | 2 | — | |
| Change in valuation of investment securities | −48,000 | 8 | 596,000 | — | — | |
| Change in fair value of contingent consideration | −1 | 7 | −3 | −17 | −4 | |
| Other | 2 | 4 | −2 | −45,000 | 1 | |
| Accounts receivable | −2 | −10 | −10 | −7 | −7 | |
| Inventories | −11 | −6 | −58 | −33 | −10 | |
| Prepaid expenses and other current assets | −4 | 593,000 | 2 | −874,000 | −3 | |
| Accounts payable | 3 | −6 | 9 | 2 | 4 | |
| Other current liabilities | −2 | 10 | 4 | 627,000 | 1 | |
| Contingent consideration milestone payment | −1 | — | — | — | −7 | |
| Other long-term assets and liabilities | −4 | −9 | 27,000 | −2 | −5 | |
| Net cash provided by (used in) operating activities | 33 | 26 | −46 | −12 | 18 | |
| Capital expenditures | −35 | −35 | −62 | −23 | — | |
| Cash acquired in SeaSpine merger | — | — | 29 | — | — | |
| Sale of investment securities | — | 7 | — | 126,000 | — | |
| Other investing activities | 28,000 | −100,000 | −500,000 | 126,000 | −1 | |
| Net cash used in investing activities | −35 | −28 | −33 | −25 | −23 | |
| Proceeds from credit facilities | — | 198 | 175 | — | — | |
| Repayment of borrowings from credit facilities | — | −143 | −79 | — | — | |
| Payment of debt acquired from SeaSpine merger | — | — | −27 | — | — | |
| Proceeds from issuance of common shares | 6 | 6 | 5 | 4 | 9 | |
| Payments related to withholdings for share-based compensation | −432,000 | −5 | −4 | −2 | −3 | |
| Contingent consideration milestone payment | −5 | −1 | −1 | — | — | |
| Payments related to finance lease obligation | −762,000 | −706,000 | −652,000 | −3 | −537,000 | |
| Payment of debt issuance costs and other financing activities | −531,000 | −4 | −2 | −92,000 | −948,000 | |
| Net cash provided by (used in) financing activities | −786,000 | 51 | 65 | −78,000 | −4 | |
| Effect of exchange rate changes on cash and restricted cash | 1 | −938,000 | 619,000 | −997,000 | −815,000 | |
| Net change in cash, cash equivalents, and restricted cash | −623,000 | 48 | −13 | −37 | −9 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro